A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis (MS)

Interventions

DRUG: Ocrelizumab
DRUG: Ocrelizumab
DRUG: rHuPH20

Sponsor

Hoffmann-La Roche